Phase I and II Trials in Cancer
The Duke Center for Applied Therapeutics (DCAT) has a long history of developing vaccines and treatments to activate the immune system against various cancers. Currently accruing studies include:
For Advanced HER2+ Breast Cancer
VRP-HER2 vaccine + anti-PD-1 antibody (Pembrolizumab)
This is a study for people who have advanced breast cancers that are HER2 positive and are receiving therapy that includes the antibodies trastuzumab and pertuzumab. In addition to their standard treatment, study participants receive the VRP-HER2 vaccine or the pembrolizumab or both.
For Surgically Treated ER+ Breast Cancer
Estrogen Receptor (ER) Peptide Vaccine
This is a study for people who have had surgery for an ER+ breast cancer and have no evidence of the cancer. In addition to their hormone therapy, study participants receive injections of a vaccine that activates the immune system against abnormal forms of the ER protein.
For Surgically Treated Cancers
HER3 DNA Vaccine
This is a study for people who have had surgery for any type of HER3 expressing cancer and have completed their chemotherapy and radiation and have no evidence of the cancer. Study participants receive injections of a vaccine that activates the immune system against a protein called HER3 which is found on many breast cancers.